Loading
companiesCompany
Agilent Technologies (Dako)
Agilent makes the Dako PD-L1 IHC 22C3 and 28-8 companion diagnostics and the Omnis staining platform.
Overview
Agilent Technologies, based in Santa Clara and listed as A, makes the Dako PD-L1 IHC 22C3 and 28-8 companion diagnostics and the Omnis staining platform. Its pathology reagents and instruments sit alongside mass spectrometry and genomics tools, and its PD-L1 assays are tied to the pembrolizumab and nivolumab labels; OnCo also links it to HER2 IHC and ISH companion assays and to Resolution ctDx FIRST. It connects to reference laboratories, companion diagnostics, histopathology and immunohistochemistry and IHC autostainers. Whether the multiplicity of PD-L1 assays can be harmonised, or whether each drug keeps its own test, is the open question its products embody. PD-L1 IHC 22C3 pharmDx has its own page.
Headquarters
Santa Clara, CA, US
Scorecard
All companies#201of 1244 companies, score 27
- approved products +18
- targets +6
- modalities +2
- regions +1
3 approved, 0 in phase 3, 0 earlier, 3 targets, 0 registry studies. Formula on the scorecards page.
Type
Diagnostics · A
Stage
Public
Website
ApprovedHER2 immunohistochemistry and in situ hybridisation companion diagnostic assays
HER2 IHC and ISH companion assays (HercepTest, PATHWAY 4B5, HER2 Dual ISH) · HercepTest / PATHWAY anti-HER2 (4B5) / INFORM HER2 Dual ISH
The tests that grade a breast or stomach cancer's HER2 level, from the original trastuzumab test in 1998 to the new 'HER2-low' and 'ultralow' cut-offs.
ApprovedPD-L1 immunohistochemistry companion diagnostic assay
PD-L1 IHC 22C3 pharmDx · PD-L1 IHC 22C3 pharmDx
The 22C3 pharmDx assay is the PD-L1 stain tied to pembrolizumab since 2015 and the source of the combined positive score (CPS). The cut-off differs by cancer: 1% of tumour cells in lung cancer, CPS 1 in gastric, cervical and head and neck cancer, CPS 10 in oesophageal and triple-negative breast cancer, so one stain is read differently per disease.
ApprovedLiquid biopsy companion diagnostic test (NGS, cfDNA)
Resolution ctDx FIRST · Resolution ctDx FIRST
A blood test approved with adagrasib to find the KRAS G12C mutation in lung cancer when a tissue biopsy is not possible.
Similar pages
- CompanyLeica Biosystems (Danaher)
Shares Histology automation and IHC autostainers, Reference laboratories and companion-diagnostic testing, Histopathology & immunohistochemistry and the tag supporting.
- CompanyLabcorp
Shares Reference laboratories and companion-diagnostic testing, Companion diagnostics and the tag supporting.
- CompanySakura Finetek
Shares Histology automation and IHC autostainers and the tag supporting.
- CompanyQuest Diagnostics
Shares Reference laboratories and companion-diagnostic testing and the tag supporting.
- CompanyNeoGenomics
Shares Reference laboratories and companion-diagnostic testing and the tag supporting.
- TechnologyPre-analytics: blood-collection tubes and tissue fixation
Shares Reference laboratories and companion-diagnostic testing, Histopathology & immunohistochemistry and the tag supporting.
- CompanyQIAGEN
Shares Companion diagnostics and the tag supporting.
- TechnologyWhole-slide scanners and image management
Shares Histology automation and IHC autostainers and the tag supporting.
fronts
technologies
drugs
ApprovedHER2 immunohistochemistry and in situ hybridisation companion diagnostic assays
HER2 IHC and ISH companion assays (HercepTest, PATHWAY 4B5, HER2 Dual ISH) · HercepTest / PATHWAY anti-HER2 (4B5) / INFORM HER2 Dual ISH
ApprovedPD-L1 immunohistochemistry companion diagnostic assay
PD-L1 IHC 22C3 pharmDx · PD-L1 IHC 22C3 pharmDx
ApprovedLiquid biopsy companion diagnostic test (NGS, cfDNA)
Resolution ctDx FIRST · Resolution ctDx FIRST